Description
This LLM model is trained to perform Q&A, Summarization, RAG, and Chat
How to use
document_assembler = DocumentAssembler()\
.setInputCol("text")\
.setOutputCol("document")
medical_llm = MedicalLLM.pretrained("jsl_medm_q16_v1", "en", "clinical/models")\
.setInputCols("document")\
.setOutputCol("completions")\
.setBatchSize(1)\
.setNPredict(100)\
.setUseChatTemplate(True)\
.setTemperature(0)
pipeline = Pipeline(
stages = [
document_assembler,
medical_llm
])
medm_prompt = """
summarize the following content.
content:
---------------------------- INDICATIONS AND USAGE ---------------------------
KISUNLA is an amyloid beta-directed antibody indicated for the
treatment of Alzheimer’s disease. Treatment with KISUNLA should be
initiated in patients with mild cognitive impairment or mild dementia
stage of disease, the population in which treatment was initiated in the
clinical trials. (1)
------------------------DOSAGE AND ADMINISTRATION-----------------------
• Confirm the presence of amyloid beta pathology prior to initiating
treatment. (2.1)
• The recommended dosage of KISUNLA is 700 mg administered as
an intravenous infusion over approximately 30 minutes every four
weeks for the first three doses, followed by 1400 mg every four
weeks. (2.2)
• Consider stopping dosing with KISUNLA based on reduction of
amyloid plaques to minimal levels on amyloid PET imaging. (2.2)
• Obtain a recent baseline brain MRI prior to initiating treatment.
(2.3, 5.1)
• Obtain an MRI prior to the 2nd, 3rd, 4th, and 7th infusions. If
radiographically observed ARIA occurs, treatment
recommendations are based on type, severity, and presence of
symptoms. (2.3, 5.1)
• Dilution to a final concentration of 4 mg/mL to 10 mg/mL with 0.9%
Sodium Chloride Injection, is required prior to administration. (2.4)
----------------------DOSAGE FORMS AND STRENGTHS---------------------
Injection: 350 mg/20 mL (17.5 mg/mL) in a single-dose vial. (3)
------------------------------- CONTRAINDICATIONS ------------------------------
KISUNLA is contraindicated in patients with known serious
hypersensitivity to donanemab-azbt or to any of the excipients. (4, 5.2)
------------------------WARNINGS AND PRECAUTIONS-----------------------
• Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical
vigilance for ARIA is recommended during the first 24 weeks of
treatment with KISUNLA. Risk of ARIA, including symptomatic
ARIA, was increased in apolipoprotein E ε4 (ApoE ε4)
homozygotes compared to heterozygotes and noncarriers. The risk
of ARIA-E and ARIA-H is increased in KISUNLA-treated patients
with pretreatment microhemorrhages and/or superficial siderosis. If
a patient experiences symptoms suggestive of ARIA, clinical
evaluation should be performed, including MRI scanning if
indicated. (2.3, 5.1)
• Infusion-Related Reactions: The infusion rate may be reduced, or
the infusion may be discontinued, and appropriate therapy initiated
as clinically indicated. Consider pre-treatment with antihistamines,
acetaminophen, or corticosteroids prior to subsequent dosing. (5.3)
-------------------------------ADVERSE REACTIONS------------------------------
Most common adverse reactions (at least 10% and higher incidence
compared to placebo): ARIA-E, ARIA-H microhemorrhage, ARIA-H
superficial siderosis, and headache. (6.1)
"""
data = spark.createDataFrame([[medm_prompt]]).toDF("text")
results = pipeline.fit(data).transform(data)
results.select("completions").show(truncate=False)
val document_assembler = new DocumentAssembler()
.setInputCol("text")
.setOutputCol("document")
val medical_llm = MedicalLLM.pretrained("jsl_medm_q16_v1", "en", "clinical/models")
.setInputCols("document")
.setOutputCol("completions")
.setBatchSize(1)
.setNPredict(100)
.setUseChatTemplate(True)
.setTemperature(0)
val pipeline = new Pipeline().setStages(Array(
document_assembler,
medical_llm
))
val medm_prompt = """
summarize the following content.
content:
---------------------------- INDICATIONS AND USAGE ---------------------------
KISUNLA is an amyloid beta-directed antibody indicated for the
treatment of Alzheimer’s disease. Treatment with KISUNLA should be
initiated in patients with mild cognitive impairment or mild dementia
stage of disease, the population in which treatment was initiated in the
clinical trials. (1)
------------------------DOSAGE AND ADMINISTRATION-----------------------
• Confirm the presence of amyloid beta pathology prior to initiating
treatment. (2.1)
• The recommended dosage of KISUNLA is 700 mg administered as
an intravenous infusion over approximately 30 minutes every four
weeks for the first three doses, followed by 1400 mg every four
weeks. (2.2)
• Consider stopping dosing with KISUNLA based on reduction of
amyloid plaques to minimal levels on amyloid PET imaging. (2.2)
• Obtain a recent baseline brain MRI prior to initiating treatment.
(2.3, 5.1)
• Obtain an MRI prior to the 2nd, 3rd, 4th, and 7th infusions. If
radiographically observed ARIA occurs, treatment
recommendations are based on type, severity, and presence of
symptoms. (2.3, 5.1)
• Dilution to a final concentration of 4 mg/mL to 10 mg/mL with 0.9%
Sodium Chloride Injection, is required prior to administration. (2.4)
----------------------DOSAGE FORMS AND STRENGTHS---------------------
Injection: 350 mg/20 mL (17.5 mg/mL) in a single-dose vial. (3)
------------------------------- CONTRAINDICATIONS ------------------------------
KISUNLA is contraindicated in patients with known serious
hypersensitivity to donanemab-azbt or to any of the excipients. (4, 5.2)
------------------------WARNINGS AND PRECAUTIONS-----------------------
• Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical
vigilance for ARIA is recommended during the first 24 weeks of
treatment with KISUNLA. Risk of ARIA, including symptomatic
ARIA, was increased in apolipoprotein E ε4 (ApoE ε4)
homozygotes compared to heterozygotes and noncarriers. The risk
of ARIA-E and ARIA-H is increased in KISUNLA-treated patients
with pretreatment microhemorrhages and/or superficial siderosis. If
a patient experiences symptoms suggestive of ARIA, clinical
evaluation should be performed, including MRI scanning if
indicated. (2.3, 5.1)
• Infusion-Related Reactions: The infusion rate may be reduced, or
the infusion may be discontinued, and appropriate therapy initiated
as clinically indicated. Consider pre-treatment with antihistamines,
acetaminophen, or corticosteroids prior to subsequent dosing. (5.3)
-------------------------------ADVERSE REACTIONS------------------------------
Most common adverse reactions (at least 10% and higher incidence
compared to placebo): ARIA-E, ARIA-H microhemorrhage, ARIA-H
superficial siderosis, and headache. (6.1)
"""
val data = Seq(medm_prompt).toDF("text")
val results = pipeline.fit(data).transform(data)
results.select("completions").show(truncate=False)
Results
KISUNLA is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease. It is recommended to initiate treatment in patients with mild cognitive impairment or mild dementia stage of disease. The recommended dosage is 700 mg administered as an intravenous infusion over approximately 30 minutes every four weeks for the first three doses, followed by 1400 mg every four weeks. Patients should have a recent baseline brain MRI prior to initiating treatment and obtain an MRI prior to the 2nd,
Model Information
| Model Name: | jsl_medm_q16_v1 |
| Compatibility: | Healthcare NLP 5.5.0+ |
| License: | Licensed |
| Edition: | Official |
| Language: | en |
| Size: | 12.7 GB |